FDA Review of Novavax’s COVID-19 Vaccine—Regulatory Integrity and Deviations From Standard Practice
This Viewpoint notes that the review and communication processes for the Novavax COVID-19 vaccine deviated from standard practice and raises concerns if this is the “new normal” for the FDA.
Authors
- Patricia J. Zettler (ORCID: https://orcid.org/0000-0001-9114-0735)
- Peter Lurie (ORCID: https://orcid.org/0000-0001-7867-4951)
- Sarah Despres
- Stephen Cha
Institutions
- Center for Science in the Public Interest (United States) (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1001/jama.2025.9898
- Citations
- 5
- Primary Topic
- Vaccine Coverage and Hesitancy
- Type
- article
- Field-Weighted Citation Impact
- 10.84